Compare Ascendis Pharma A/S (ASND) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs PayPal Holdings, Inc. — how do they compare? Ascendis Pharma A/S trades at $264.44 (market cap $17.74B), while PayPal Holdings, Inc. trades at $46.95 (market cap $40.86B). The key difference: PayPal Holdings, Inc. is far larger — about 2.3× Ascendis Pharma A/S's market cap, and PayPal Holdings, Inc. pays a 1.21% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PYPL | |
|---|---|---|
Market Cap | $17.74B | $40.86B |
Sector | Health | Financials |
52-Week High | $277.18 | $78.22 |
52-Week Low | $163.32 | $39.08 |
Enterprise Value | $18.11B | $40.93B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
PayPal (PYPL) trades at $46.32, up 2.21% today, with a bullish technical signal and strong fundamentals including a low P/E of 8.69 and robust net income margin of 15%. Recent earnings beat expectations in Q1 2026, and the company is targeting $1.5B in AI-driven savings to fuel growth. The stock is near resistance at $46, with support at $44.
PYPL presents a value opportunity with attractive valuation multiples and steady revenue growth, but faces competition and margin pressure. Analyst consensus is mixed with a $48.36 price target, indicating modest upside. Risks include execution challenges and macroeconomic headwinds, yet strong cash flow supports shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
